Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, was the lead author of an article recently published in The Lancet Gastroenterology & Hepatology. Dr. Kowdley and team conducted a Phase 2 trial investigating the efficacy of rusfertide in treating HFE-related haemochromatosis (an inherited iron overload disorder caused by insufficient hepcidin production). Rusfertide prevented iron re-accumulation in the absence of phlebotomies and could be a viable therapeutic option for some patients with haemochromatosis.
Read the full study in The Lancet Gastroenterology & Hepatology: https://www.thelancet.com/journals/langas/article/PIIS2468-1253%2823%2900250-9/fulltext
